Ada­gio adopts new name, adds Covid cock­tail can­di­date in ‘new day’ bid af­ter ini­tial drug de­vel­op­ment woes

Ada­gio is now In­vivyd.

More than just a brand name change though, the biotech is adding a new Covid-19 drug can­di­date and look­ing for a re­freshed start af­ter a tu­mul­tuous stretch in Covid-19 drug de­vel­op­ment.

Along with the new In­vivyd name, it an­nounced on Mon­day a new an­ti­body cock­tail can­di­date for Covid pre­ven­tion and treat­ment with stud­ies set to be­gin in Q1 2023. The new NVD200 com­bines two mon­o­clon­al an­ti­bod­ies aimed at Omi­cron vari­ants, and adds to the com­pa­ny’s ef­forts on its late-stage Covid can­di­date ad­in­tre­vimab which was coast­ing along on a raft of pos­i­tive da­ta be­fore Omi­cron emerged.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER